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Background: We evaluated the association between linear standard Heart Rate Variability (HRV) measures and
vascular, renal and cardiac target organ damage (TOD).
Methods: A retrospective analysis was performed including 200 patients registered in the Regione Campania
network (aged 62.4 ± 12, male 64%). HRV analysis was performed by 24-h holter ECG. Renal damage was assessed
by estimated glomerular filtration rate (eGFR), vascular damage by carotid intima-media thickness (IMT), and cardiac
damage by left ventricular mass index.
Results: Significantly lower values of the ratio of low to high frequency power (LF/HF) were found in the patients
with moderate or severe eGFR (p-value < 0.001). Similarly, depressed values of indexes of the overall autonomic
modulation on heart were found in patients with plaque compared to those with a normal IMT (p-value <0.05).
These associations remained significant after adjustment for other factors known to contribute to the development
of target organ damage, such as age. Moreover, depressed LF/HF was found also in patients with left ventricular
hypertrophy but this association was not significant after adjustment for other factors.
Conclusions: Depressed HRV appeared to be associated with vascular and renal TOD, suggesting the involvement
of autonomic imbalance in the TOD. However, as the mechanisms by which abnormal autonomic balance may
lead to TOD, and, particularly, to renal organ damage are not clearly known, further prospective studies with
longitudinal design are needed to determine the association between HRV and the development of TOD.
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Cardiovascular (CV) diseases are one of the most leading
causes of morbidity and mortality in high developed
countries [1]. A number of prospective population or co-
hort studies, such as the Atherosclerosis Risk in Commu-
nities Study [2], the Rotterdam Study [3], the
Cardiovascular Health Study [4], and the Carotid Athero-
sclerosis Progression Study [5], have shown that asymp-
tomatic organ damage is significantly related to incident
CV events. If CV involvement is early detected by physi-
cians, it is possible to influence the progression or regres-
sion of the disease by the therapy [6]. Although there is
still a little information on the specific causes of these
pathologies, a recent review by Thayer suggested that
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reproduction in any medium, provided the orincreased morbidity and mortality from a host of condi-
tions and pathologies, including CV diseases [7]. Analysis
of heart rate variability (HRV) on the basis of routine
24-hour Holter recordings has been shown to provide a
sensitive measurement of cardiac control by the autono-
mous nervous system (ANS) [8,9]. HRV is a non-invasive
measure reflecting the variation over time of the period
between consecutive heartbeats (RR intervals) [8]. In fact,
heart rate (HR), which continuously fluctuates over time,
is under the influence of control mechanisms aimed at
maintaining a dynamic stability called homoeostasis [10].
In this equilibrium, the sympathetic stimulation causes
acceleration in HR by increasing the firing rate of pace-
maker cells in the heart’s sino-atrial node, while the para-
sympathetic system causes deceleration in HR by
decreasing of the firing rate of pacemaker cells [8]. Clin-
ical studies have shown reduced HRV in patients with
congestive heart failure [11-16], diabetes [17], and whiteLtd. This is an Open Access article distributed under the terms of the Creative
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iginal work is properly cited.
Melillo et al. BMC Cardiovascular Disorders 2012, 12:105 Page 2 of 11
http://www.biomedcentral.com/1471-2261/12/105coat hypertension [18]. Moreover, decreased HRV mea-
sures have been shown to be a risk factor for mortality in
chronic haemodialysis patients [19] and for progression
to end-stage renal disease [20,21]. Furthermore, several
studies have shown that incidence of CV events can be
reduced by therapeutic correction of any modifiable risk
factors, such as hypertension, abnormal cholesterol, dia-
betes, smoking habit or physical inactivity. As noted and
shown in the review by Thayer [7], there is at least some
data to suggest that each of these risk factors is asso-
ciated with decreased HRV. Regarding hypertensive
patients a sympatho-vagal imbalance as evaluated by
HRV with increased sympathetic activity and reduced
vagal tone has been reported [22] and a recent paper by
Garcia-Garcia [23] investigate the correlation between
heart rate and the parameters that assess vascular, renal
and cardiac target organ damage (TOD). However, only
two HRV measures were selected in the study by Garcia-
Garcia [23]. The aim of the current study was to evaluate
the association between linear standard HRV measures
with the vascular, renal and cardiac TOD in hypertensive
patients registered in the Campania Salute network. The
Campania Salute network is an open registry collecting
information from a network of general practitioners and
community hospitals networked with the centre, and
providing a centralised database including demographics
and clinical information of the patients.Methods
Population study
For the present study, among the initial cohort of 12,000
patients registered in the database of the Campania Sa-
lute Network, we selected all the hypertensive subjects
who underwent at least one visit in the Outpatient
Hypertension Clinic of the University of Naples “Federico
II” from 2000 to 2010 and were evaluated by a cardiac
and carotid ultrasonography and by a 24h Holter ECG.
The ECG Holter was performed after a one-month anti-
hypertensive therapy wash-out. Details on this cohort
have been previously reported [24,25]. Exclusion criteria
for the present analysis were: diagnosis of secondary re-
sistant and/or uncontrolled hypertension, prevalent CV
disease, clinical history of cancer, liver cirrhosis and/or
failure, narcotics abuse, lifestyle changes in the last
12 months. Moreover, patients with atrial fibrillation
and frequent ectopic beats as assessed by Holter were
excluded. Prevalent CV disease was defined as history
of previous myocardial infarction or angina or procedures
of coronary revascularization, stroke or transitory ische-
mic attack, congestive heart failure, chronic kidney disease
more than grade 3 (eGFR by MDRD < 30mL/min/1.73m2)
at the time of the first examination in the outpatient
clinic. Prevalent CV disease was excluded by an ad-hoccommittee in the Hypertension Centre, based on patients’
history, contact with the referring general practitioner
and clinical records documenting the occurrence of dis-
ease. In the sub-cohort of 10254 patients with arterial
hypertension, 4257 patients were excluded for diagnosis
of secondary resistant and/or uncontrolled hypertension,
prevalent CV disease, clinical history of cancer, liver cir-
rhosis and/or failure, narcotics abuse, lifestyle changes in
the last 12 months; 1814 for chronic kidney disease more
than grade 3 (eGFR by MDRD < 30mL/min/1.73m2);
2556 for missing data (i.e. ultrasonography, holter ECG);
942 for atrial fibrillation and 485 for frequent ectopic
beats.
Ethical issues
All the data of the patients (i.e. medical history, physical
examination, routine laboratory tests and other diagnos-
tic procedures) were stored in the computerised database
of Campania Salute Network. The database generation of
the Campania Salute Network was approved by the Fed-
erico II University Hospital Ethic Committee. All the par-
ticipants signed informed consent to use data for
scientific purposes.
Protocol
At the first visit all patients were given a detailed question-
naire inquiring about specifics lifestyle behaviours and
smoking habit. In the current study they were categorised
as non-smokers, ex-smokers or smokers. During the visits,
blood pressure (BP), lipid and glucose profiles were mea-
sured for each patient by standard methods. Diagnosis
and stratification of essential hypertension was performed
according to the criteria established by the Guidelines for
the Management of Arterial Hypertension [26]: systolic
and diastolic BP were measured by a standard aneroid
sphygmomanometer after 5 min rest in the supine pos-
ition, according to the current guidelines [26]. Three BP
measurements were obtained at 2-min intervals. The
averages of these measurements were used for the ana-
lysis. Glomerular filtration rate (eGFR) was estimated by
the Modification of Diet in Renal Disease (MDRD) for-
mula [27]. Diabetes was defined as a fasting blood glucose
≥126 mg/dL or active glucose-lowering therapy [28].
Echocardiography
Two-dimensional-guided M-mode echocardiograms were
performed using a dedicated ultrasound machine (SONOS
5500, Philips) with an ultrasound transducer of 2.5 MHz.
The examinations were recorded on a digital recorder and
analysed by three independent, trained and experienced
physicians. The parameters relative to the left ventricle
(LV) were measured in the parasternal long-axis view and
obtained, according to the criteria of the American Society
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measurements, as also performed in previous studies
[30,31]. LV mass was determined by using the formula
developed by Devereux [32] as recommend by American
Society of Echocardiography (ASE) [33] and divided by
the body surface area to calculate LV mass index (LVMi,
g/m2). Intraoperator and interassay variability were 5%
and 6%, respectively [34].Table 1 Characteristics of the study sample of patients
Characteristic Value
Age (years) 62.5 ± 12.1
Sex (male/female, %) 63.5/36.5
Family history of hypertension (yes/no, %) 56.5/43.5
Family history of stroke (yes/no, %) 19.5/80.5
Smokers (yes/ex/no, %) 17.5/21/61.5Carotid ultrasound
B-mode ultrasonography of carotid arteries was per-
formed with patients in the supine position with the neck
extended in mild rotation. The scanning protocol was per-
formed with an ultrasound device (SONOS 5500, Philips)
equipped with a 7.5-MHz high-resolution transducer with
an axial resolution of 0.1 nm. Examinations were recorded
on S-VHS videotapes. All measurement were analysed by
three different trained experienced physicians. An average
of two readings was considered for subsequent calcula-
tions. The accuracy of determinations was evaluated as
previously described by Lembo et al. [35]: the variability of
measurements to evaluate intrasonographer and interso-
nographer reproducibility was 0.01 and 0.03 mm, respect-
ively. The maximum arterial intima media thickness
(IMT) in up to 12 arterial walls, including the right and
the left, near and far distal common carotid (1 cm), bifur-
cation, and proximal internal carotid artery was estimated
offline with an image processing workstation with the
software COMPACS (Rev. 10.5.8, Medimatic, Genoa,
Italy).Diabetes (yes/no, %) 10/90
Diastolic BP (mmHg) 75.6 ± 12.0
Systolic BP (mmHg) 133.2 ± 22.6
Pulse pressure (mmHg) 57.6 ± 17.8
Fasting blood glucose (mmHg) 102.7 ± 24.1
Total Cholesterol (mg/dl) 185.8 ± 40.6
BMI (kg/m2) 27.7 ± 4.6
Beta-blockers (yes/no, %) 33.5/66.5
Alphabeta-blockers (yes/no, %) 10.5/89.5
Alpha-blockers (yes/no, %) 8/92
Diuretics (yes/no, %) 43.5/56.5
ACE inhibitor (yes/no, %) 37.5/62.5
Dihydropyridine (yes/no, %) 26/74
eGFR (mL/min/1.73 m2) 77.0 ± 18.9
Kidney Involvement (group 1/ 2 /3 %) 24/59.5/16.5
IMT (mm) 2.24 ± 1.56
Vascular abnormalities (no/ thickening/plaque, %) 13/11/78
LVMi g/m2 130.5 ± 31.0
Left Ventricular hypertrophy (no/yes, %) 40/60
Data are expressed as mean and standard deviation for continuous variables
(i.e. age) and as percentage of patients per each group for categorical
variables (i.e. gender).Assessment of TOD
Cardiac Involvement was evaluated as Left Ventricular
Hypertrophy (LVH) which was diagnosed if LVMi
exceeded 110 g/m2 in female and 125 g/m2 in male [36].
Vascular involvement was assessed as carotid artery ath-
erosclerosis shown by increased IMT in B-mode ultrason-
ography. IMT values between 1.0 and 1.3 mm were
defined as "thickening" and those higher than 1.3 mm as
“plaque”. Chronic kidney disease was assessed by eGFR
and involvement was quantified as follows:
1. group 1: increased or normal eGFR (eGFR ≥
90 mL/min/1.73 m2)
2. group 2: mild eGFR (60 < eGFR < 90 mL/min/
1.73 m2)
3. group 3: moderate eGFR (eGFR ≤ 60 mL/min/
1.73 m2) [37]
Processing 24-hour holter recordings
On 2 consecutive days, patients underwent a 24-hour
ECG Holter recording. The recorders were applied be-
tween 9 and 11 AM on a working day, and the patientswere asked to follow as closely as possible their usual daily
activities during each monitoring session. They were asked
to stay in bed from 11 PM to 7 AM, and all reported to
have slept normally during the nights they were moni-
tored. The series of normal to normal (NN) beat intervals
were obtained from ECG recordings using OSAS, an
open-source software for QRS detection and beat classifi-
cation [38]. Standard long-term HRV analysis on nominal
24-h recordings according to International Guidelines was
performed [8]. The HRV analysis was performed using
PhysioNet's HRV Toolkit [39]. We chose this toolkit as it
is an open source and a rigorously validated package. All
the computed basic time- and frequency-domain HRV
measures were widely used in the literature [8]. A number
of standard statistical time-domain HRV measures are cal-
culated: Average of all NN intervals (AVNN), standard de-
viation of all NN intervals (SDNN), standard deviation of
the averages of NN intervals in all 5-min segments of a
24-h recording (SDANN), mean of the standard deviations
of NN intervals in all 5-min segments of a 24-h recording
(SDNN IDX), square root of the mean of the sum of the
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(RMSSD), percentage of differences between adjacent NN
intervals that are longer than 50 ms (pNN50). The
frequency-domain HRV measures rely on the estimation
of power spectral density (PSD) computed, in this work,
by Lomb-Scamble periodogram [40]. After PSD estima-
tion, six standard frequency-domain HRV measures were
calculated: total spectral power of all NN intervals up to
0.4 Hz (TOTPWR), between 0 and 0.003 Hz (ULF), be-
tween 0.003 and 0.04 Hz (VLF), between 0.04 and 0.15 Hz
(LF), and between 0.15 and 0.4 Hz (HF), ratio of low to
high frequency power (LF/HF).Statistical analysis
Data were analysed by the use of PASW Statistics 18 soft-
ware (Release 18.0; SPSS IBM, Chicago, IL, USA). Uni-
variate differences were analysed using Kruskal-Wallis
and Wilcoxon test for HRV measures, ANOVA and t-
test for the other continuous variables (for instance age,
IMT, etc.) and χ2 test for the categorical variables (forTable 2 Characteristics of the study sample of patients stratif
Normal
eGFR
(group 1)
Mild
decreased
eGFR
(group 2)
Age (years) 56 ± 11.5 63,0 ± 11.7
Gender (male/female) 31/17 76/43
Family history of hypertension (yes/no) 25/23 69/50
Family history of stroke (yes/no) 11/37 22/97
Smokers (yes/ex/no) 13/8/27 8/27/7
Diabetes (yes/no) 5/43 11/108
Diastolic BP (mmHg) 73.2 ± 14.0 77.3 ± 11.5
Systolic BP (mmHg) 124.5 ± 23.3 137.5 ± 20.0
Pulse pressure (mmHg) 51.3 ± 14.1 60.1 ± 16.9
Fasting blood glucose (mmHg) 99.7 ± 32.2 102.8 ± 20.0
Total Cholesterol (mg/dl) 178.9 ± 36.4 187.7 ± 40.8
BMI (kg/m2) 27.4 ± 5.2 28.1 ± 4.6
Beta-blockers (yes/no) 15/33 41/78
Alphabeta-blockers (yes/no) 5/43 14/105
Alpha-blockers (yes/no) 3/45 8/111
Diuretics (yes/no) 17/31 49/70
ACE inhibitor (yes/no) 16/32 48/71
Dihydropyridine (yes/no) 12/36 30/89
eGFR (mL/min/1.73 m2) 101.9 ± 12.0 74.3 ± 8.8
IMT (mm) 1.8 ± 0.76 2.23 ± 1.21
Vascular abnormalities (no/ thickening/plaque) 33/6/9 91/13/15
LVMi g/m2 124.3 ± 26. 2 133.0 ± 32.3
Left Ventricular hypertrophy (no/yes) 24/24 44/75
Data are expressed as mean and standard deviation for continuous variables (i.e. ag
(i.e. gender).
The p-values refer to ANOVA and post-hoc comparisons with Bonferroni correctionsinstance sex, smoking). For each HRV measure, which
differs significantly among the three groups, an adjusted
model was proposed by performing a binary or multi-
nomial logistic regression, as appropriate. For each factor
or covariate, the coefficient of the estimated regression
model (β), the corresponding statistical significance (p),
the odds ratio (OR) and the confidence interval for OR at
95% are presented. A p-value less than 5% was consid-
ered statistically significant.Results
200 patients were analysed (127 male and 73 female).
Demographic, clinical and laboratory characteristics of
the study sample are shown in Table 1. Table 2 shows the
characteristic of the study sample of patients categorised
by eGFR. The moderate eGFR group is significantly older
than the others and has a significantly higher proportion
of patients taking diuretics. Systolic BP and Pulse Pres-
sure values were significantly higher in mild decreased
eGFR group (compared to normal eGFR group), whereied according to the eGFR
Moderate
decreased
eGFR
(group 3)
P Values
ANOVA or
χ2
group 1 vs
group 2
group 1 vs
group 3
group 2 vs
group 3
70.0 ± 9.4 <0.001 0.001 <0.001 0.05
20/13 0.928
19/14 0.778
6/27 0.790
27/75/21 0.379
4/29 0.883
73.0 ± 9.8 0.048 0.129 1 0.185
130.2 ± 27.3 0.002 0.002 0.754 0.286
57.3 ± 23.3 0.014 0.010 0.396 1
106.7 ± 23.9 0.432 1 0.589 1
189.0 ± 45.8 0.395 0.610 0.817 1
26.7 ± 3.5 0.261 1 1 0.379
11/22 0.924
2/31 0.639
5/28 0.252
21/12 0.03
11/22 0.604
10/23 0.826
50.6 ± 8.0 <0.001 <0.001 <0.001 <0.001
2.91 ± 2.85 0.007 0.282 0.005 0.81
28/3/2 0.502
130.4 ± 32.1 0.258 0.301 1 1
12/21 0.268
e) and as number of patients per each group for categorical variables
for continuous variables, to χ2 for categorical variables.
Table 3 Comparisons of HRV measurement in patients stratified by eGFR
Normal eGFR (group 1) Mild decreased eGFR (group 2) Moderate decreased eGFR (group 3) P-values
Mean St. Dev. Quartiles Mean St. Dev. Quartiles Mean St. Dev. Quartiles
1st 2nd 3rd 1st 2nd 3rd 1st 2nd 3rd
AVNN 859.7 109.4 784.1 848.9 916.8 867.8 136.4 774.9 853.5 954.4 884.4 119.0 793.6 875.4 963.4 0.525
SDNN 125.7 30.2 101.9 119.5 146.1 119.4 38.8 92.2 111.1 140.1 116.6 36.1 94.7 113.6 141.1 0.280
SDANN 113.4 32.5 90.1 108.6 137.0 106.6 38.7 78.0 99.4 129.1 105.2 36.1 81.2 104.0 132.4 0.308
SDNN IDX 51.9 11.8 43.2 51.4 58.9 51.2 16.5 40.7 47.4 61.1 45.4 13.7 36.2 44.3 58.3 0.168
RMSSD 32.6 12.5 24.4 30.1 38.1 35.7 18.9 22.6 30.7 42.3 35.6 14.3 24.4 33.5 42.1 0.602
pNN50 8.8 6.6 3.8 7.7 11.9 11.2 10.4 2.8 7.9 17.8 11.5 11.0 4.1 9.7 12.9 0.714
TOTPWR 18224 8902 11002 16124 23743 17498 12477 8919 13736 21744 17099 10273 9648 14338 24713 0.354
ULF 14919 8093 8797 12379 18709 14098 10139 7083 10675 18458 14311 8999 7867 11539 20217 0.368
VLF 1815 843 1184 1592 2384 1872 1417 961 1471 2416 1368 835 780 1254 1959 0.071
LF 861 522 481 711 1108 823 795 368 601 922 660 460 344 543 925 0.123
HF 629 502 293 471 743 705 715 205 496 815 760 602 251 527 1230 0.626
LF/HF 1.74 0.92 1.17 1.44 2.11 1.48 0.90 0.91 1.25 1.75 1.00 0.47 0.71 0.85 1.25 <0.001
St. Dev. standard deviation.
The p-values refer to Kruskal-Wallis test.
Table 4 Characteristics of the study sample of patients stratified according to IMT
Normal Thickening Plaque P Values
ANOVA or
χ2
Normal vs
Thickening
Normal vs
Plaque
Thickening vs
Plaque
Age (years) 47.3 ± 13.3 57.0 ± 9.6 65.9 ± 9.8 <0.001 0.004 <0.001 0.001
Sex (male/female) 16/10 10/12 101/51 0.157
Family history of hypertension (yes/no) 16/10 18/4 79/73 0.026
Family history of stroke (yes/no) 4/22 6/16 29/123 0.564
Smokers (yes/ex/no) 4/3/19 6/2/14 25/37/90 0.242
Diabetes (yes/no) 2/24 1/21 17/135 0.572
Diastolic BP (mmHg) 76.5 ± 10.8 73.4 ± 18.6 75.8 ± 11.1 0.643 1 1 1
Systolic BP (mmHg) 131.5 ± 19.2 124.1 ± 33.2 134.8 ± 21.1 0.106 0.768 1 0.113
Pulse pressure (mmHg) 55.0 ± 14.9 50.6 ± 19.9 59.0 ± 17.8 0.086 1 0.856 0.117
Fasting blood glucose (mmHg) 98.0 ± 20.7 95.7 ± 22.0 104.5 ± 24.7 0.154 1 0.601 0.321
Total Cholesterol (mg/dl) 182.0 ± 38.0 192.0 ± 39.1 185.6 ± 41.4 0.687 1 1 1
BMI (kg/m2) 28.8 ± 5.4 27.3 ± 3.7 27.6 ± 4.6 0.395 0.747 0.596 1
Beta-blockers (yes/no) 15/11 6/16 46/106 0.019
Alphabeta-blockers (yes/no) 1/25 3/19 17/135 0.465
Alpha-blockers (yes/no) 1/25 2/20 13/139 0.702
Diuretics (yes/no) 9/17 8/14 70/82 0.429
ACE inhibitor (yes/no) 10/16 8/14 57/95 0.989
Dihydropyridine (yes/no) 7/19 4/18 41/111 0.675
eGFR (mL/min/1.73 m2) 84.1 ± 17.5 81.2 ± 17.8 75.2 ± 19.1 0.045 1 0.077 0.479
Renal involvement 9/15/2 6/13/3 33/91/28 0.502
IMT (mm) 0.89 ± 0.11 1.19 ± 0.08 2.62 ± 1.61 <0.001 1 <0.001 <0.001
LVMi g/m2 109.6 ± 19.0 126.7 ± 33.2 134.6 ± 30.9 <0.001 0.149 <0.001 0.744
Left Ventricular hypertrophy (no/yes) 20/6 11/11 49/103 <0.001
Data are expressed as mean and standard deviation for continuous variables (i.e. age) and as number of patients per each group for categorical variable (i.e. gender).
The p-value refers to ANOVA and post-hoc comparison with Bonferroni corrections for continuous variables and to χ2 for categorical variables.
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group (compared to moderate decreased eGFR group).
Table 3 shows the descriptive statistics of HRV measures
in the groups stratified by eGFR. The three groups dif-
fered significantly in LF/HF. Table 4 shows the character-
istic of the study sample of patients categorised by IMT.
The Plaque group is significantly older than the others.
LVMi values were significantly lower in the normal group
compared to the Plaque group and the proportion of
patients with LVH was significantly lower. A significantly
higher proportion of patients with family history of
hypertension was assessed in the Thickening group. A
significant difference in the proportion of patients taking
beta-blockers was observed. Table 5 shows the descrip-
tive statistics of HRV measures in the three groups
according to IMT. The three groups differed significantly
in SDNN, SDANN, SDNN IDX TOTPWR, LF, and LF/
HF. Table 6 shows the characteristic of the study sample
of patients categorised by LVH. The LVH group is signifi-
cantly older than the group without LVH. IMT values
were significantly higher in the LVH group and the pro-
portion of patients with vascular abnormalities was sig-
nificantly higher. A significantly higher proportion of
patients taking diuretics was assessed in LVH group. The
values of Systolic BP and Pulse Pressure were signifi-
cantly higher in the LVH group. Table 7 shows the com-
parison of HRV measures in the patients with and
without LVH. The two groups differed significantly in
LF/HF. Most differences persisted even in the adjusted
models, which are reported in Table 8. As concerns renal
TOD, the multinomial logistic regression selected age,
family history of hypertension and systolic BP. Higher
values of LF/HF are associated with an increasedTable 5 Comparisons of HRV measurement in the group of pa
Normal IMT Thicke
Mean St. Dev. Quartiles Mean St. Dev.
1st 2nd 3rd 1
AVNN 830.0 123.5 749.2 821.6 916.2 842.3 141.8 74
SDNN 140.1 48.8 105.3 132.3 171.3 121.7 34.3 9
SDANN 128.4 49.7 88.2 124.8 157.9 110.8 34.7 8
SDNN IDX 58.9 19.0 44.4 55.2 73.1 50.7 13.8 4
RMSSD 36.9 13.5 26.8 32.2 42.6 30.7 11.7 2
pNN50 12.5 9.1 5.9 8.2 16.5 9.2 9.1 2
TOTPWR 24209 16727 12113 19664 31647 17583 10891 9
ULF 19550 13805 9436 16075 25947 14453 9137 7
VLF 2590 1944 1113 2117 3172 1746 1101 1
LF 1255 1040 471 1006 1863 819 627 4
HF 813 685 305 542 1299 566 517 1
LF/HF 1.78 0.98 1.05 1.53 2.25 2.02 1.25 1
St. Dev. standard deviation.
The p-values refer to Kruskal-Wallis test.probability that a subject belongs to normal or mild
eGFR groups rather than to moderate group (OR
2.718 and 2.637, respectively). Older age is associated
with a decreased probability of being in normal or
mild decreased eGFR groups (OR 0.897 and 0.943, re-
spectively). The absence of family history of hyperten-
sion is associated with an increased probability of
belonging to normal eGFR group (OR 2.951). Elevated
systolic BP seems to be associated with a slightly increased
probability of belonging to mild decreased eGFR group
(OR 1.024). As regards vascular TOD, the adjusted mod-
els confirmed the differences in the values of SDNN and
SDANN. In fact, higher values of SDNN and SDANN are
associated with an increased probability that a subject
had no vascular alterations rather than plaque. Moreover,
this model confirms that older age is associated with vas-
cular alterations. As regards cardiac TOD, the binomial
logistic regression did not confirm the difference in LF/
HF and showed that other variables are associated with
LVH such as age, systolic BP, cholesterol, and diuretics.
Discussion
To our knowledge, the current study is the first one to
investigate standard linear HRV measures, both in time
and in frequency domains, in hypertensive patients, cate-
gorised by severity of TOD at different levels (cardiac,
vascular and renal) and considering adjusted models
for age and other clinical parameters (such as gender,
metabolic variables). Time and power spectral analysis
of 24-hour electrocardiographic monitoring was per-
formed in 200 hypertensive patients in basal conditions.
At these same times, patients underwent echocardio-
graphic and carotid ultrasonography study evaluationstients stratified by IMT
ning Plaque P-value
Quartiles Mean St. Dev. Quartiles
st 2nd 3rd 1st 2nd 3rd
6.7 820.5 957.3 879.0 124.7 797.1 864.8 952.0 0.116
4.2 115.3 147.2 116.9 33.3 93.3 111.6 136.9 0.049
1.0 102.2 138.3 104.1 33.5 80.3 98.5 124.1 0.046
3.0 48.9 56.5 49.0 14.2 38.8 47.4 59.5 0.042
2.1 29.7 34.0 35.2 17.9 22.7 30.5 41.7 0.216
.8 6.1 11.3 10.6 10.0 3.1 8.3 15.5 0.195
798 14497 22534 16480 9863 9300 13860 21255 0.049
958 11822 18562 13420 8327 7216 10942 17851 0.092
091 1514 1862 1640 1027 960 1325 2251 0.052
93 688 934 726 595 357 568 934 0.009
78 499 617 694 661 229 477 914 0.376
.14 1.55 2.71 1.33 0.75 0.82 1.13 1.68 0.002
Table 6 Characteristics of the study sample of patients
with and without LVH
LVH P values
Patient Group
with LVH
Patient group
without LVH
Age (years) 56.8 ± 12.1 66.3 ± 10.6 0.001
Sex (male/female) 49/31 78/42 0.589
Family history of
hypertension (yes/no)
48/32 65/55 0.415
Family history of stroke
(yes/no)
15/65 24/96 0.827
Smokers (yes/ex/no) 17/18/45 18/24/78 0.404
Diabetes (yes/no) 2/78 18/102 0.004
Diastolic BP (mmHg) 73.8 ± 12.1 76.8 ± 11.8 0.094
Systolic BP (mmHg) 126.1 ± 25.3 137.9 ± 19.4 0.001
Pulse pressure (mmHg) 52.3 ± 18.0 61.1 ± 16.8 0.001
Fasting blood glucose
(mmHg)
99.8 ± 23.6 104.7 ± 24.3 0.161
Total Cholesterol (mg/dl) 191.0 ± 38.6 182.3 ± 41.7 0.132
BMI (kg/m2) 27.2 ± 4.3 28.0 ± 4.8 0.235
Beta-blockers (yes/no) 31/49 36/84 0.199
Alphabeta-blockers
(yes/no)
7/73 14/106 0.510
Alpha-blockers (yes/no) 5/75 11/109 0.456
Diuretics (yes/no) 25/55 62/58 0.004
ACE inhibitor (yes/no) 25/55 50/70 0.136
Dihydropyridine (yes/no) 17/63 35/85 0.211
eGFR (mL/min/1.73 m2) 79.9 ± 17.9 75.1 ± 19.5 0.071
Kidney Involvement (1/2 /3) 24/44/12 24/75/21 0.268
IMT (mm) 1.82 ± 0.93 2.52 ± 1.82 <0.001
Vascular abnormalities
(no/ thickening/plaque)
20/11/49 6/11/103 <0.001
LVMi g/m2 105.0 ± 13.8 147.5 ± 27.3 <0.001
Data are expressed as mean and standard deviation for continuous variables
(i.e. age) and as number of patients per each group for categorical variable
(i.e. gender).
The p-values refer to t-test for continuous variables and χ2 for categorical
variables.
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http://www.biomedcentral.com/1471-2261/12/105and routine laboratory evaluations in order to assess
TOD at different level. The data of the current study
showed that significantly lower values of some HRV
measures were found in patients with CV involvement
at different levels. Particularly, decreased LF/HF, which
is a marker of sympatho-vagal balance, was found in
the patients with moderate decreased eGFR, the highest
grade of kidney involvement considered in this study.
Similarly, depressed values of indexes of the overall ANS
modulation on the heart, such SDNN and SDANN,
were found in patients with plaque compared to patients
with a normal IMT. These associations remained sig-
nificant after adjustment for other factors known to con-
tribute to the development of TOD, including diabetes,hypertension, and metabolic variables. Moreover, depressed
LF/HF was found also in patients with LVH but this
association was not significant after adjustment for other
factors. As stated in a recent paper by Garcia-Garcia [23]
the association between HRV and the development of
TOD or vascular alterations has not been clearly estab-
lished. Garcia-Garcia [23] investigated the association
between 24-hours heart rate and IMT, LVMi, and
eGFR, by performing a cross-sectional study including
360 hypertensive patients without heart rate lowering
drugs, aged 30–80 years. We underline that they com-
puted only two HR parameters: the mean HR and the
standard deviation of HR (which are similar to AVNN
and SDNN computed in the current study, respectively),
while in this study almost all the linear HRV measures
were computed as recommended and standardised in
International Guidelines [8] and confirmed by recent
literature [9]. Moreover, we proposed a larger number
of covariates than Garcia-Garcia [23] in the adjusted
model, for instance, the familiarity for hypertension or
stroke. They found no association between AVNN and
SDNN with LVH, consistently with our results. More-
over, they found associations between AVNN and SDNN
with respect to IMT and eGFR, but these were lost after
adjusting for age. Our results were coherent with these
findings, even if in our studies the association of SDNN
with IMT was significant also after adjustment. However,
the patients in the study by Garcia-Garcia [23] were
younger (56 ± 11 years versus 62 ± 12 years) and with a
lower percentage of heart (18% vs 60%), and vascular
(23% vs 75%) TOD. Moreover, the HRV analysis in this
study was performed after a one-month antihypertensive
therapy wash-out while many patients in the sample
studied by Garcia-Garcia received drug therapy (not HR
lowering drugs). We underline that the therapy before
ECG holter measurement among selected groups was
comparable as no significant differences occurred. The
only exception was represented by diuretics, as a larger
proportion of patients in the moderate eGFR group
assumed diuretics compared with the other two groups
(mild and normal eGFR) and a larger proportion of
patients in the hypertrophy group assumed them com-
pared to the group without hypertrophy. This difference
was due to the fact that the antihypertensive treatment of
patients with moderate decreased eGFR or with hyper-
trophy was based on the combination of diuretics with
other drugs (i.e. Beta-blockers, ACE inhibitor, AT1
Antagonist and Dihydropyridine) which were usually pre-
scribed also in the other groups of patients. We underline
that the association of diuretics with a lower HRV has
been already shown by the ARIC study [41] in 3577 hyper-
tensive patients and by a recent study [42] in general male
population, for that reason we performed the HRV ana-
lysis after a drug washout. The comparison of our results
Table 7 Comparisons of HRV measurement in the group of patients with and without LVH
Patients with LVH Patients without LVH P values
Mean St. Dev. Quartiles Mean St. Dev. Quartiles
1st 2nd 3rd 1st 2nd 3rd
AVNN 846.9 121.8 772.6 829.5 916.8 883.1 129.2 789.9 863.7 963.8 0.071
SDNN 123.5 37.0 101.5 118.3 142.3 118.4 36.0 91.8 112.7 142.4 0.247
SDANN 111.2 37.6 88.0 106.7 128.7 105.9 36.3 79.4 99.0 129.5 0.304
SDNN IDX 51.9 15.0 42.7 49.5 60.8 49.5 15.2 38.5 47.8 58.4 0.127
RMSSD 32.8 14.5 22.9 29.2 36.4 36.4 18.1 23.1 32.4 42.3 0.123
pNN50 9.9 10.3 3.2 7.1 11.9 11.2 9.4 3.4 9.2 17.0 0.163
TOTPWR 18472 12108 10873 15952 21928 17029 10776 8958 14057 22697 0.288
ULF 15018 10082 8177 12029 18491 13872 9043 7093 11412 18656 0.347
VLF 1892 1255 1074 1668 2393 1697 1206 923 1336 2086 0.105
LF 896 782 429 704 1092 744 619 369 556 912 0.072
HF 666 694 210 483 757 716 622 261 502 965 0.316
LF/HF 1.74 0.99 1.03 1.60 2.08 1.28 0.74 0.81 1.03 1.51 <0.001
St. Dev. standard deviation.
The p-values refer to Wilcoxon test.
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of computing several HRV parameters, especially the
frequency-domain measures, such as LF/HF, which is con-
sidered as a non-invasive marker of the sympatho-vagal
balance. However, the plausible mechanisms by which
abnormal autonomic balance may lead to TOD and,
particularly, renal organ damage one are not clearly
known. Our results were consistent with two recent
studies [20,21], investigating HRV and kidney disease,
which concluded that lower HRV (particularly, frequency
domain measures) was associated with higher risk of pro-
gression to end-stage renal disease and suggested that
autonomic imbalance may lead to kidney damage. For
that reason, prospective longitudinal studies are needed
to evaluate a causal effect between HRV and TOD. In
future studies, additional HRV measures, derived from
nonlinear [43] and/or point process time-frequency [44]
analysis, could be selected either in short-term record-
ings under standardised conditions [45] or in long-term
continuous monitoring [46]. Moreover, other non-invasive
parameters related to ANS activity, such as pupillometric
features [47,48], could be adopted to provide additional
information on autonomic cardiac control. As regards
the other factors which entered the adjusted models, the
age is the most significant variable, confirming that car-
diac, vascular, and renal abnormalities increase progres-
sively with age [49,50]. The absence of hypertensive
familiarity seems to be associated with no renal involve-
ment. Significantly higher systolic BP values were found
in the mild decreased eGFR group, maybe because the
blood pressure values are controlled in patients with
moderate renal eGFR by the (significantly higher) use of
diuretics. Higher systolic BP values were associated withLVH, coherently with the fact that it is an established car-
diac manifestation of chronic hypertension [51]. More-
over, other factors associated with LVH are higher
assumption rate of diuretics and higher values of choles-
terol. Although previous studies have shown that gender
influences HRV parameters both in healthy subjects [52]
and hypertensive patients [53], this factor entered no final
adjusted models. This means that within the selected
sample of patients the gender-related differences in HRV
were smaller than differences related to other factors and
covariates, in particular age or progression of TOD. We
consider in any case that the main limitations of this
study were the inherent ones of observational and cross-
sectional design, which precludes longitudinal analysis
between HRV and TOD.
Conclusions
In conclusion, depressed HRV appeared to be associated
with vascular and renal TOD. In particular, depressed
values of indexes of the overall ANS modulation on heart
were found in patients with plaque compared to those
with a normal IMT. These associations remained sig-
nificant after adjustment for other factors known to con-
tribute to the development of TOD. Moreover LF/HF, a
marker of sympatho-vagal balance, was significant-
ly decreased in the groups with mild and moderate
decreased eGFR, confirming the involvement of auto-
nomic imbalance in TOD. However, as the mechanisms
by which abnormal autonomic balance may lead to TOD
are not clearly known, we suggested that further pro-
spective studies with longitudinal design would be per-
formed to investigate HRV in the early stages of
hypertension and of TOD development.
Table 8 Multinomial or binary logistic regression models
Compared groups HRV measure, factor or covariate β p OR 95% CI of OR
Normal eGFR versus Moderate decreased eGFR Intercept 5.971 0.021
LF/HF 1.000 0.038 2.718 1.057 to 6.984
Systolic BP −0.003 0.779 0.997 0.974 to 1.020
Age −0.109 <0.001 0.897 0.847 to 0.948
Absence of family history of hypertension 1.082 0.047 2.951 1.014 to 8.588
Mild decreased eGFR versus Moderate decreased eGFR Intercept 0.527 0.819
LF/HF 0.969 0.034 2.637 1.075 to 6.465
Systolic BP 0.024 0.027 1.024 1.003 to 1.046
Age −0.058 0.020 0.943 0.898 to 0.991
Absence of family history of hypertension 0.710 0.122 2.034 0.827 to 5.001
Normal IMT group versus Plaque group1 Intercept 5.552 0.002
SDNN 0.018 0.024 1.018 1.002 to 1.033
Age −0.169 <0.001 0.844 0.796 to 0.896
Absence of family history of hypertension 0.347 0.532 1.415 0.476 to 4.211
Thickening group versus Plaque group1 Intercept 2.688 0.101
SDNN 0.005 0.446 1.005 0.992 to 1.019
Age −0.080 0.001 0.923 0.879 to 0.970
Absence of family history of hypertension −1.072 0.071 0.342 0.107 to 1.096
Normal IMT group versus Plaque group1 Intercept 5.777 0.001
SDANN 0.017 0.021 1.017 1.003 to 1.032
Age −0.169 <0.001 0.845 0.797 to 0.696
Absence of family history of hypertension 0.357 0.523 1.429 0.478 to 4.270
Thickening group versus Plaque group1 Intercept 2.626 0.101
SDANN 0.006 0.351 1.006 0.993 to 1.020
Age −0.080 0.001 0.923 0.879 to 0.970
Absence of family history of hypertension −1.059 0.075 0.347 0.108 to 1.112
group with Hypertrophy versus group without Hypertrophy2 Intercept −5.240 0.004 0.005
LF/HF −0.155 0.528 0.856 0.563 to 1.302
Age 0.068 <0.001 1.071 1.036 to 1.107
Cholesterol −0.006 0.141 0.994 0.986 to 1.002
Diuretics −0.854 0.011 0.426 0.220 To 0.823
β: regression coefficient.
p: p-value referred to each variable in the regressions (multinomial or binary logistic).
OR: odds ratio, which is exp(β).
95% CI: 95% confidence interval.
1 multinomial logistic regression.
2 binary logistic regression.
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